The muscarinic M₁ receptor modulates associative learning and memory in psychotic disorders

Geor Bakker a,b,c, Claudia Vingerhoets b,c, Oswald J.N. Bloemen a,c, Barbara J. Sahakian d, Jan Boort b, Matthijs W.A. Caan e, Therèse A.M.J. van Amelsvoort a

a Department of Psychiatry and Psychology, University of Maastricht, Maastricht, The Netherlands
b Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, The Netherlands
c Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
d Department of Psychiatry and Psychology, University of Maastricht, Maastricht, The Netherlands
e Department of Biomedical Engineering and Physics, Amsterdam University Medical Centres, Location AMC, University of Amsterdam, Amsterdam, The Netherlands

A B S T R A C T

Background: Psychotic disorders are characterized by prominent deficits in associative learning and memory for which there are currently no effective treatments. Functional magnetic resonance imaging (fMRI) studies in psychotic disorders have identified deficits in fronto-temporal activation during associative learning and memory. The underlying pathology of these findings remains unclear. Postmortem data have suggested these deficits may be related to loss of muscarinic M₁ receptor mediated signaling. This is supported by an in-vivo study showing improvements in these symptoms after treatment with the experimental M₁/₄ receptor agonist xanomeline. The current study tests whether reported deficits in fronto-temporal activation could be mediated by loss of M₁ receptor signaling in psychotic disorders.

Methods: Twenty-six medication-free subjects diagnosed with a psychotic disorder and 29 age-, gender-, and IQ-matched healthy controls underwent two functional magnetic resonance imaging (fMRI) sessions, one under placebo and one under selective M₁ antagonist biperiden, while performing the paired associated learning task. M₁ binding potentials (BPND) were measured in the dorsolateral prefrontal cortex (DLPFC) and hippocampus using 123I-IDEX single photon emission computed tomography.

Results: In the subjects with psychotic disorders DLPFC hypoactivation was only found in the memory phase of the task. In both learning and memory phases of the task, M₁ antagonism by biperiden elicited significantly greater hyperactivation of the parahippocampal gyrus and superior temporal gyrus in subjects with a psychotic disorders compared to controls. Greater hyperactivation of these areas after biperiden was associated with greater hippocampal M₁ receptor binding during learning, with no association found with M₁ receptor binding in the DLPFC. M₁ receptor binding in the DLPFC was related to greater functional sensitivity to biperiden in the cingulate gyrus during the memory phase.

Conclusion: The current study is the first to show differences in M₁ receptor mediated functional sensitivity between subjects with a psychotic disorder and controls during a paired associate learning and memory task. Results point to subjects with psychotic disorders having a loss of M₁ receptor reserve in temporal-limbic areas.

1. Introduction

Psychotic disorders affect approximately 3% of the general population (Perälä et al., 2007). Aside from the positive and negative symptoms, psychotic disorders are characterized by cognitive impairments that develop in approximately 80 to 85% of patients. These symptoms often develop before the onset of the other symptoms and have been found to be the strongest predictor of illness progression and relapse (Green et al., 2004). Cognitive symptoms do not respond to currently available antipsychotic treatments and persist even after other symptoms have been treated. Although several domains of cognition are affected, executive functioning and learning and memory processes have been shown to be most impaired (Barch and Ceaser, 2012; Murray et al., 2010; Sheffield et al., 2018). Specifically patients with psychotic disorders have deficits in associative learning and memory. Through associative learning and memory relationships between unrelated items are encoded and retrieved and rely on both executive functioning and learning and memory processes. Severity of these deficits have been shown to be an important predictor of poor functional outcome, and exist independent of poor concentration, administered medication, and presence of positive symptoms (Barch and Sheffield, 2014; Barnett et al., 2005).

Using functional magnetic resonance imaging (fMRI), studies have investigated alterations in underlying brain activation during associative learning and memory in psychotic disorders. Significant hypo-activation of the dorsolateral prefrontal cortex (DLPFC) and increased activation of the parahippocampal gyrus are most consistently reported (Ragland et al., 2012, 2009, 2004). It has been suggested that findings
of the increased parahippocampal gyrus activation may be a compensatory mechanism. Meta-analytical studies, however, highlight a high level of inconsistencies in reported results (Kruguljac et al., 2013). These inconsistencies have mainly been attributed to the high heterogeneity among patient cohorts studied, with patients in different phases of the disorder (first episode to chronic) and under different antipsychotic treatment regimens (Kruguljac et al., 2013). Impairments in associative learning and memory processes have shown little to no improvement under antipsychotic treatment and recently it has been proposed that lowered signaling of the muscarinic system, a system not targeted by most antipsychotic treatments, could underlie these abnormalities (Carruthers et al., 2015; Erskine et al., 2019). This neurotransmitter system became implicated after studies showed reversible deficits in associative learning and memory after administration of anti-muscarinic agents in healthy subjects and subjects with neurodegenerative disorders (Mufson et al., 2003). Similar to subjects with psychotic disorders, functional MRI showed attenuation of activation in the DLPFC after administration of anti-muscarinic agents to healthy volunteers (Grasby et al., 1995). Preclinical data identified that these effects were most likely driven by the muscarinic M1 receptor subtype rather than the other muscarinic receptor subtypes (M2,3,5). The M1 receptor subtypes has high expression rates in fronto-limbic brain regions which are critically involved in associative learning and memory (Anagnostaras et al., 2003; Carruthers et al., 2015; Levey et al., 1991).

The potential loss of M1 receptor functioning in psychotic disorders was first supported by human post-mortem studies showing significantly reduced M1 receptor expression in the DLPFC of schizophrenia patients compared to controls (Dean et al., 2002; Scarr et al., 2013). Empirical in-vivo evidence, however, for lower M1 receptor functioning in psychotic disorders is more limited. Experimental drug xanomeline, which is a M1/M4 preferring receptor agonist, has been shown to improve learning and memory scores in schizophrenia patients, and in keeping with these results, we showed lower M1 receptor binding in-vivo in the DLPFC was associated with worse verbal learning and memory scores in psychotic disorders (Bakker et al., 2018; Shelkar et al., 2006a). However, it is still unclear whether loss of M1 related modulation of DLPFC and hippocampus activation during associative learning and memory drives deficits in psychotic disorders, as xanomeline’s effects on cognition may be related to the drug’s affinity for both M1 and M4 receptors, which are also highly expressed in the hippocampus and striatum. Recent preclinical data highlights the importance of the balance between M1 and M4 signaling for learning and memory, suggesting that it may in fact be the disruption of this balance driving deficits seen in psychotic disorders (Gould et al., 2018; Thorn et al., 2017).

Taken together it is still unknown what role M1 receptor mediated signaling plays in associative learning and memory deficits of psychotic disorders in-vivo. Although loss of M1 receptor specific modulation on associative learning and memory is best studied using a selective M1 agonist drug, these drugs are still in early phases of development and not yet available for research in humans. Selective M1 antagonists, however, are available and well tolerated, therefore, we choose to investigate differences in M1 mediated functional reactivity in psychotic disorders and controls using a challenge with the M1 antagonist biperiden. We were also interested in modeling how loss of M1 related signaling translated to abnormalities in functional activation underlying associative learning and memory. Therefore, we examined whether functional reactivity to biperiden in subjects with psychotic disorders was related to M1 receptor binding in the DLPFC and hippocampus using single photon emission computed tomography (SPECT). Based on previous studies on associative learning and memory we anticipate that subjects with psychotic disorders will show (1) hypo-activation of the prefrontal cortex and increased parahippocampal gyrus activation during associative learning and memory compared to controls, and that (2) biperiden will attenuate this task-induced activation in the DLPFC in both groups, with subjects with psychotic disorders showing smaller reduction in activation under biperiden. Biperiden will also lead to task induced increased parahippocampal gyrus activation which will be greater in controls than the subjects with psychotic disorders. Lastly, we anticipate that (3) subjects with psychotic disorders with lower DLPFC and hippocampal M1 receptor binding will show greater hypo-activation in the prefrontal cortex and increased activation in parahippocampal regions during associative learning and memory.

2. Materials and methods

2.1. Participants

The current study included 26 subjects with a psychotic disorder and 29 healthy control subjects matched for age, gender, and IQ. All subjects with a psychotic disorder were medication-free and were recruited from early detection and intervention programs, the national first episodic psychosis network, and through advertisements in newspapers. The 26 subjects diagnosed with a psychotic disorder also participated in another study (Bakker et al., 2018). In the previous study, 30 psychotic disorders subjects were included, but only 26 of them were willing to also participate in the current fMRI study. Diagnosis of a DSM-IV psychotic disorder was confirmed using the Comprehensive Assessment of Symptoms and History (CASH) semi-structured interview (Andreasen et al., 2000). For an overview of the psychotic disorders included in the study see table 1 of sample demographic variables. Duration of untreated psychosis was not allowed to be longer than 1 year, and both subjects with psychotic disorders and control subjects needed to be 18 years of age or older. Exclusion criteria were contraindications for MRI, severe neurological or endocrine disorders, current use of recreational drugs and pregnancy, which were checked through urine samples. Due to the administration of biperiden subjects with tardive dyskinesia and narrow angle glaucoma were excluded. Psychotic symptom severity at time of scanning was determined using the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987). Ethical approval was obtained from the Amsterdam University Medical Centres Medical Ethical Committee. Written informed consent was obtained from all participants after complete description of the study.

2.2. Procedures

All subjects underwent 2 functional MRI sessions on separate days, one after the oral administration of a placebo and one after the oral administration of 4 mg of biperiden, in a counterbalanced and randomized controlled trial. Biperiden is a well-tolerated muscarinic receptor antagonist with a 10-fold higher binding affinity for the M1 receptor subtype over the other muscarinic receptor subtypes (Kimura et al., 1999). Scans were conducted 90 min after biperiden administration at which peak plasma levels of biperiden have been reached (Grimaldi et al., 1986). Biperiden (Akineton) instant release tablets were used (Knoll AG, Ludwigshafen, Germany). Only subjects that were diagnosed

| Table1 Demographic variables. | Psychotic Disorder | Controls | stat | p |
|-----------------------------|-------------------|---------|------|---|
| N                           | 26                | 29      |      |   |
| Gender (male/female)        | 19/7 (20/9)       | 0.12    | 0.7  |   |
| Age in years (M/SD)         | 27.7 (4.9)        | 25.6 (5.2) | −1.51 | 0.14 |
| IQ (M/SD)                   | 102 (16)          | 109 (16) | 1.78 | 0.081 |
| Psychotic disorder subtype  |                   |         |      |   |
| Schizophrenia               | 11                |         |      |   |
| Schizoaffective disorder    | 2                 |         |      |   |
| Schizophreniform disorder   | 2                 |         |      |   |
| Psychosis NOS               | 11                |         |      |   |
| Number of episodes:         | 1/2/3             | 18/6/2  |      |   |
with a psychotic disorders received an additional single photon emission computed tomography (SPECT) scan to quantify $M_1$ receptor binding using the $M_1$ preferring radiotracer iododextrimide ($^{123}$I$\text{-IDE})$ (Bakker et al., 2015). These subjects received two 100 mg iodide tablets the night before and one tablet in the morning of the day of scanning to prevent thyroid uptake of free radioactive iodide. Each subject received a bolus injection of approximately 185 MBq (5 mCi) 6h prior to SPECT scanning. Further details of radioisynthesis and binding characteristics of $^{123}$I$\text{-IDE}$ are extensively described elsewhere (Bakker et al., 2015; Lavalaye et al., 2001).

2.3. fMRI task paradigm

In order to assess the modulatory role $M_1$ mediated signaling on functional response during associative learning and memory we adapted the paired associate learning task (PAL) of the Cambridge Neuropsychological Test Automated Battery (CANTAB) for MRI (De Rover et al., 2011). Similar to the PAL CANTAB version of the task, subjects were presented with a black screen displaying white boxes. Each box opened randomly for 3 s, with four or more containing a pattern. After all boxes had opened and closed, a figure would appear in the center and the subject had to identify the original box it was shown in (learning phase). The same trial would be repeated showing the same figures in the same boxes again after which subjects were asked to identify the box the figure had appeared in (memory phase). Cognitive load was increased as the task progressed with subjects having to learn 4, 6, and 8 figure-place associations. Cognitive load was increased as the task progressed with subjects having to learn 4, 6, and 8 figure-place associations. Figure-place associations were presented randomly to control for practice effects between sessions. No figure was be presented twice within the same session. Subjects selected a box by navigating a red square around a box to the correct location using the right index finger and middle finger, and the left index finger was used to confirm the location. The experimental design was an event-related design with a learning and memory phase followed by a control phase in which subjects had to select the box to which the arrow was pointing. The task was programmed using E-prime software. For an overview of the task see Fig. 1.

2.4. Image acquisition and parameters

All functional magnetic resonance (fMRI) images were acquired using a Philips Ingenia 3.0 Tesla system (Phillips, Best, The Netherlands) using gradient echo echo-planar imaging (EPI) with a 32-channel head sense coil. 37 slices were scanned with 3-mm isotropic voxel size with a repetition time of 2s, and an echo time of 27 ms. Additionally, a structural T1 weighted anatomical MPRAGE scan was made (180 slices, voxel size $1 \times 1 \times 1$ mm, TR: 7.0 ms, TE: 3.2 ms) for co-registration of functional images, and SPECT images in the psychotic disorders group. $^{123}$I$\text{-IDE}$ SPECT images were obtained using a brain-dedicated camera (inSpira HD, Neurologica, Boston, USA) (Stam et al., 2018). Acquisition, attenuation correction, and reconstruction of the SPECT images was performed as described in Bakker et al., 2018.

2.5. Data analyses

Statistical analysis of group demographic variables was conducted using IBM SPSS release 24 (SPSS Inc. Chicago IL, USA). Normality of distribution was tested for all dependent variables using Kolmogorov-Smirnov and Shapiro-Wilk test. Group differences in gender were assessed using a chi-square test. Group differences in age and IQ were assessed with an independent samples $t$-test, and changes in psychotic symptom severity between placebo and biperiden conditions were assessed using a paired samples $t$-test. Behavioral responses on the PAL task were extracted using E-prime and analyzed using IBM SPSS version 24. A 2 factor (group and medication) by 2 level (group: psychotic disorders/controls and medication: placebo/biperiden) ANCOVA was used to assess main effect of group, medication, and group by medication interactions on performance accuracy for 4, 6, and 8 figure place associations controlling for counterbalance order. Group differences between accuracy for 4, 6, and 8 figure place associations were assessed using a paired samples $t$-test.

All preprocessing and statistical analysis of functional images were done using FEAT (fMRI expert analysis tool) implemented in FSL 6.0.0 (FMRIB’s software library). All functional images were skull stripped, realigned, corrected for slice timing, spatially normalized, resampled to the Montreal Neurological Institute (MNI) 2 mm template, and smoothed using a 5 mm full width at half maximum Gaussian kernel. First level contrast images were created by modelling signal changes during learning and memory phases in comparison to the control condition (see Fig. 1), convolved with a canonical hemodynamic response function. Six standard rigid body motion parameters were estimated.
and a confound matrix of volumes corrupted by motion effects greater than two standard deviations was added to the model. A multi-level (hierarchical) statistical analysis was done to identify group differences and effects of medication, and group by medication interaction effects. The group by medication interaction effect was the main analysis of interest. First, the mean response over the three sessions of increasing learning and memory load (4, 6, and 8 figure–place associations) were pooled using a fixed effects analysis using FILM modeling tool (FMRIB's Improved Linear Model). Resulting contrast parameter estimates were assessed in a higher level 2-way mixed effects ANOVA using FLAME 1 + 2 (FMRIB's Local Analysis Local Analysis of Mixed Effect) to assess the main effect of medication (placebo/biperiden) and group (psychosis/controls) by medication interaction effect. To test the main effect of group and group differences a separate higher-level model was run. For this analysis within-subject mean effect of medication was pooled in a fixed effects analysis and resulting contrast parameter estimates were analysed using a 2 group mean comparison controlling for IQ and accuracy. Activity was considered significant if Z > 3.1 with a multiplicity correction.

Lastly, analysis of the SPECT images was done as earlier described (Bakker et al., 2018), and these data were used to examine how functional reactivity was related to within subject in-vivo M₁ receptor binding in psychotic disorders. M₁ receptor binding was quantified in terms of the binding potential (BPND) which is a tissue ratio of specific to non-specific binding. Specific binding was measured as 123I-IDEX binding in the M₁-rich hippocampus and DLPFC, and non-specific binding was measured in cerebellar gray matter which is devoid of M₁ receptors. These regions were delineated on subject’s own T1 weighted image using Freesurfer (Fischl et al., 2002), as earlier described (Bakker et al., 2018). Relationship between M₁ receptor binding and functional reactivity to biperiden during learning and memory was assessed using a fixed effects analysis with M₁ binding added as covariate regressor, controlling for task performance accuracy.

3. Results

3.1. Demographic variables

Subjects did not differ significantly in age, gender, or IQ. The subjects with psychotic disorders reported mild psychotic symptoms and no difference in psychotic symptom severity was found between scanning sessions. All subjects were antipsychotic medication-free, and 5 subjects were antipsychotic-naive. Two sessions that were being treated with a subtherapeutic dose of a non-cholinergic antipsychotic (haloperidol, 1 mg; quetiapine, 200 mg) underwent a washout (5 times the mean terminal elimination half-life of the specific antipsychotic) prior to inclusion. Sample details and statistics are summarized in Tables 1 and 2.

3.2. Cognitive performance

Estimated IQ was trend significantly (p = 0.081) lower in the subjects diagnosed with a psychotic disorder than the control group. Therefore, it was included as covariate in all further analyses.

| Clinical variables                  | Placebo | Biperiden | statistic | p     |
|------------------------------------|---------|-----------|-----------|-------|
| Psychotic disorders               |         |           |           |       |
| positive symptom severity          | 9.02 (3.2) | 9.13 (4.1) | -0.29 | 0.77  |
| negative symptom severity          | 9.41 (3.8) | 9.39 (4.0) | 0.05  | 0.91  |
| general psychopathology            | 19.81 (5.9) | 19.39 (5.4) | 0.87  | 0.39  |
| Controls                           |         |           |           |       |
| positive symptom severity          | 7.2 (0.8) | 7.1 (0.4)  | 1.01  | 0.33  |
| negative symptom severity          | 7.45 (0.3) | 7.1 (0.06) | 1.05  | 0.31  |
| general psychopathology            | 16.9 (0.37) | 16.5 (0.31) | 0.77  | 0.45  |

Correcting for IQ and counterbalance results showed a significant main effect for group on the amount of accurate responses on the PAL during the memory phase (F = 3.08 (1,26), p = 0.027), but not the learning phase. Patients were significantly worse at recalling 4, 6, and 8 figure-place associations than controls in the memory phase. There was also a significant main effect for medication (placebo vs biperiden condition) on accuracy of recall of 4, 6, and 8 figure-place associations in the memory phase, showing significantly lower accuracy scores after biperiden compared to the placebo condition in both groups (F = 4.7 (25,26), p = 0.035). No main effect of medication was found on accuracy in the learning phase. No significant group by medication interaction effect was found in either the learning or the memory phase. Post hoc paired samples t-test examining the effect of biperiden on accuracy for each cognitive load showed biperiden significantly impaired learning and memory at all cognitive loads except for the highest cognitive load of 8 figure-place associations, and the 6 and 8 figure-place associations in subjects with psychotic disorders. This may be due to a ceiling effect. Group means and standard deviations of repeated measures analyses are displayed in Table 3.

3.3. Functional reactivity

3.3.1. Psychosis vs controls

3.3.1.1. Learning phase. During the learning phase no significant main effect of group was found in functional activation between control subjects and subjects with a psychotic disorder. A significant main effect of medication (both groups showing a significant increased activation under biperiden) was found in the right superior temporal gyrus (p < 0.001; x: 64 y: −4 z: −2; Zmax: 9.28), left parahippocampal gyrus (p < 0.001; x: −30 y: −16 z: −28; Zmax: 7.58) and left precuneus (p = 0.03; x: 2 y: −66 z: 60; Zmax: 5.67). These clusters were also identified as showing a significant group by medication interaction effect (main comparison of interest), showing both controls and the subjects with a psychotic disorder having increased functional activation in these areas under biperiden, but in the subjects with a psychotic disorder this was significantly greater than in controls. See Fig. 2A. Comparisons were corrected for accuracy, IQ, and multiple comparisons.

3.3.1.2. Memory phase. A significant main effect for group was found in the left middle frontal gyrus (p < 0.001; x: −38 y: 18 z: 52; Zmax:10.5), left lateral occipital lobe (p < 0.001; x: −36 y: −74 z:44; Zmax:8.06), and fusiform cortex (p = 0.025; x:40 y: −16 z: −26; Zmax:5.99). Control subjects showed significantly greater activation in these clusters than the subjects diagnosed with a psychotic disorder. No significant main effect for medication was found. Results did show a significant group by medication interaction effect on functional activation in the right superior temporal gyrus (p = 0.01; x: −64 y: −4 z: −2; Zmax: 9.36) and left parahippocampal gyrus (p < 0.001; x: −30 y: −16 z: −28; Zmax: 4.27). The subjects diagnosed with a psychotic disorder showed significantly higher hyperactivation in these regions under biperiden, whereas control subjects showed attenuation of functional response (see Fig. 2B). All comparisons were corrected for IQ, accuracy of performance, and multiple comparisons.

3.4. Relationship between functional response to biperiden and M₁ receptor binding

In the placebo condition a significant positive correlation was found between hippocampal M₁ binding and functional activation in the left middle temporal gyrus (p = 0.036; x: −50 y: −6 z: −20; Zmax: 5.75) in the subjects diagnosed with a psychotic disorder. Lower hippocampal M₁ binding also significantly predicted a reduced functional response to biperiden during learning (smaller attenuation of activation under biperiden compared to high binders) in the left inferior temporal gyrus (p = 0.013; x: −44 y: −2 z: −30; Zmax:6.58) with significant local
peak activation within this cluster in the left fusiform gyrus (x: −40 y: −12 z: −22; Z max: 6.32) and left parahippocampal gyrus (x: −30 y: −8 z: −24; Z max: 5.82). In contrast, lower M1 binding in the DLPFC significantly predicted lower functional reactivity to biperiden (smaller attenuation of activation under biperiden) during the memory phase in the left cingulate gyrus (p < 0.001; x: −2 y:34 z: −6; Z max: 7.57) and right cingulate gyrus although this finding in the right hemisphere did not survive multiple comparison’s correction. See Fig. 3.

3.5. Relationship between functional response to biperiden and psychotic symptom severity

Greater negative symptom severity was associated with significantly lower functional reactivity to biperiden in the right caudate nucleus (p = 0.023; x: 14 y:20 z: −2; Z max:4.2) during learning, and in the left parahippocampal gyrus (p = 0.043; x: −32 y: 0 z: −24; Z max: 4.73) during the memory phase. Other psychotic symptoms did not show a significant association with functional reactivity to biperiden.

4. Discussion

The current study assessed the modulatory role of the muscarinic M1 receptor on associative learning and memory in medication-free subjects with a psychotic disorder and matched controls. In contrast to the first hypothesis, no evidence for task induced DLPFC hypoactivation was found in the subjects with a psychotic disorder compared to controls during the learning phase of the task. Biperiden also did not cause DLPFC hypoactivation in controls or further decreased DLPFC hypoactivation in the subjects with psychotic disorders. In similar vein, no evidence for increased parahippocampal gyrus activation was found in the subjects with psychotic disorders compared to controls during learning, but biperiden did induce significantly increased activation in

| Accuracy | Psychotic disorder | Controls |
|----------|-------------------|----------|
| Placebo (mean/SD) | Biperiden (mean/SD) | P | Placebo (mean/SD) | Biperiden (mean/SD) | p |
| Phase 1: Learning 4 | 3.07 (0.2) | 2.98 (0.3) | < 0.001 | 3.24 (0.2) | 3.11 (0.3) | < 0.001 |
| 6 | 3.28 (0.01) | 3.09 (0.02) | < 0.001 | 3.29 (0.02) | 3.08 (0.01) | < 0.001 |
| 8 | 4.40 (0.3) | 3.98 (0.05) | 0.002 | 4.30(0.05) | 3.99 (0.3) | < 0.001 |
| Phase 2: Memory 4 | 3.34 (0.5) | 2.88 (0.6) | < 0.004 | 4.52 (0.1) | 3.28 (0.2) | < 0.001 |
| 6 | 3.35 (0.2) | 3.33 (0.2) | 0.9 ns | 5.34 (1.1) | 3.06 (0.09) | < 0.001 |
| 8 | 3.85 (0.9) | 3.76 (0.3) | 0.7 ns | 4.66 (0.6) | 4.34 (0.9) | 0.2 ns |

All findings were corrected for IQ and counterbalance.

Fig. 2. A. Overview of clusters showing a significant group by drug interaction during the learning phase, with both groups showing significantly increased functional activation in the right superior temporal gyrus, left parahippocampal gyrus, and left precuneus under biperiden compared to placebo. In the subjects diagnosed with a psychotic disorder this hyperactivation was significantly greater compared to controls. B. Overview of clusters showing a significant group by drug interaction effect during the memory phase. Patients diagnosed with a psychotic disorder had significantly increased activation in these clusters whereas controls showed attenuation of activation. All findings were corrected for IQ, accuracy and multiple comparisons. R: right; L: left.
both subjects with psychotic disorders and controls of the parahippocampal gyrus, and this increase was significantly greater in the subjects with psychotic disorder.

In line with our hypothesis results did support significant hypoactivation of the DLPFC (left middle frontal gyrus) in the subjects with a psychotic disorder compared to controls during memory, but no evidence for increased parahippocampal gyrus activation was found. Under biperiden however, supporting the hypothesis, significant hyperactivation was found in the subjects with psychotic disorder compared to controls however, showed significant hypoactivation.

Lastly, no evidence was found for lower $M_1$ binding and patterns of greater DLPFC hypoactivation and increased parahippocampal cortex activation in the subjects with psychotic disorders during learning or memory. Instead lower hippocampal $M_1$ binding predicted lower

![Image](https://example.com/image.png)
functional response of the fusiform gyrus and parahippocampal gyrus to biperiden during learning, and lower M₁ binding in the DLPCF predicted lower functional response in the cingulate gyrus during memory.

4.1. Functional activation differences between the subjects with psychotic disorders and controls

In the current study we did not replicate findings of earlier studies in schizophrenia showing significant hypoactivation in the DLPCF and increased parahippocampal gyrus activation during associative learning, but only showed DLPCF (middle frontal gyrus) hypoactivation in the memory phase (Ragland et al., 2012, 2009, 2004). Previous studies concluded that in general the memory phase seemed to be more affected than the learning phase which is supported by our results (Barch and Sheffield, 2014). Lack of DLPCF hypoactivation during the learning phase in our cohort may be attributed to the fact that they were less ill. In the current study subjects were experiencing mild symptoms and were not as cognitively impaired as those investigated in previous studies, which may account for differences in results. In this regard, it is of interest that another previous study also did not find DLPCF hypoactivation in subjects with psychosis that were only mildly impaired (Ragland et al., 2012). Similarly, previous findings may have been confounded by use of antipsychotic medication that can affect cognitive functioning (MacKenzie et al., 2018).

4.2. Group difference in functional sensitivity to biperiden

Contrary to anticipated, biperiden did not attenuate task-induced activation in the DLPCF during associative learning, in neither control subjects, nor those diagnosed with a psychotic disorder, but instead elicited a significantly increased functional response in the parahippocampal gyrus in both groups, with patients having even greater hyperactivation. In the subjects with an psychotic disorder the greater hyperactive response was more widespread and included the superior temporal gyrus. These results suggest that loss of M₁ signalling by biperiden may have a greater impact on functional response in temporal limbic structures rather than the DLPCF. Associative learning depends on glutamate driven longterm potentiation (LTP) in the hippocampus of signals from the environment (Takeuchi et al., 2014). M₁ and M₄ critically modulate the underlying glutamergic signalling of LTP in the hippocampus. Preclinical data has shown that loss of M₁ mediated signalling leads to loss of the controlled suppression of glutamate underlying LTP leading to a hyperactive response. The significantly greater activation under biperiden in learning and memory in the psychosis patients could be driven by a greater loss in M₁ mediated suppression on glutamate in the hippocampus compared to controls, potentially due to lower reserve of M₁ receptors. Despite the subjects with psychotic disorders having very mild impairments in associative learning and memory they seem to be functionally more sensitive to M₁ antagonism than controls.

These preliminary data suggest that greater functional sensitivity of limbic structures in psychotic disorders in learning and memory may have it’s origin in loss of muscarinic M₁ mediated signalling. These findings are important, as the preclinical rodent (prenatal) methylazoxymethanol acetate (MAM) model of schizophrenia has also shown hippocampal hyperactivity from direct cell recordings (Lodge, 2013). In this model the hyperactivity translates to an increased drive on ventral tegmentum firing which results in an increased dopamine synthesis and release in the striatum (Lodge and Grace, 2011). As such, targeting the M₁ mediated signalling upstream may be beneficial to suppressing striatal hyperdopaminergia, in addition to improving cognition. Although more conclusive studies would need to be done, our data suggests that the parahippocampal gyrus hyperactivation reported in previous studies may not be a compensatory strategy as suggested but be disease mechanistic. It may also ultimately explain why hippocampal and limbic structure atrophy is seen in chronic schizophrenia (Lieberman et al., 2018).

4.3. Relationship between functional sensitivity to biperiden and M₁ receptor binding

In this study we also assessed whether differences in functional reactivity to biperiden in the subjects diagnosed with a psychotic disorder showed any direct relationship with M₁ receptor binding (Fig. 3). Results showed that levels of hippocampal M₁ binding specifically drove functional sensitivity to biperiden in limbic areas during the learning phase, with no association found for M₁ binding in the DLPCF. These results add to our previous findings showing an association between lower hippocampal M₁ binding and greater impairments in verbal learning and memory task (Bakker et al., 2018). Current results suggest this may be explained by a lower M₁ mediated functional response in limbic areas in the low binding subjects.

In contrast, M₁ binding in the DLPCF seemed to play more of a role during the memory or recall phase. It was specifically associated with greater functional sensitivity to biperiden in the bilateral cingulate gyrus (Fig. 3). The cingulate gyrus receives processed information from the hippocampus and parahippocampal gyrus to store in the cortex allowing for memory retrieval (Brem et al., 2013). Thus, lowered M₁ mediated signalling in the DLPCF seems to translate to lower activation of regions involved in the retrieval of traces formed in the learning phase. It is still unclear whether this is secondary to functional changes underlying learning processes or exist independently. Patients diagnosed with a psychotic disorder with lower M₁ binding in the DLPCF which has been hypothesised to be present in a subgroup of patients (Dean et al., 2002) may show greater impairments in memory retrieval capacity. More generally, current data show relatively greater degree of abnormalities in functional response to learning compared to memory under biperiden, suggesting psychotic disorders may be more characterised by limbic changes in muscarinic M₁ receptor sensitivity. This is in line with earlier meta-analytical studies showing greater functional abnormalities in paired associate encoding (learning) than retrieval in schizophrenia (Ragland et al., 2012).

4.4. Relationship between functional sensitivity to biperiden and severity of psychotic symptoms

The present results also showed that some of the abnormalities in functional response to biperiden were tied to negative symptom severity. Reduced functional response to biperiden in the caudate nucleus (during learning) and parahippocampal gyrus (during memory) was found in the subjects with greater negative symptoms severity. The caudate nucleus plays an important role in the association of two stimuli and hyperactivation of this area is implicated in abnormal processing of environmental cues giving rise to psychotic symptoms (McCutcheon et al., 2019). The caudate nucleus is an integral part of the fronto-striatal limbic circuitry, and although the genesis of the negative symptoms has been tied loosely to alterations in dopamine, noradrenaline and glutamate in this circuitry, the exact underlying pathology is not understood (Mitra et al., 2016). Current results seem to suggest that altered, or lower M₁ functioning may also play a role in negative symptom severity and linked to fronto-striatal-limbic functioning. This may underlie the efficacy of antipsychotic clozapine treat negative symptoms (Khan and Zaidi, 2017), and the positive effect of M₁/A agonist xanomeline on negative symptoms in patients with chronic schizophrenia (Shekhar et al., 2008b). Clozapine’s efficacy to improve negative symptoms has been attributed to the formation of its brain penetrating metabolite n-desmethylclozapine that acts a positive allosteric modulator at the M₁ receptor (Sur et al., 2003).

Taken together results from this study point to differences in functional sensitivity of the muscarinic system during learning and memory in patients diagnosed with a psychotic disorder compared to controls. This difference is particularly apparent in temporal- limbic areas and
seemingly already present in early phases of the disorder and in mildly impaired subjects. This increased muscarinic sensitivity in limbic-temporal areas in the subjects with psychotic disorders was related to hippocampal M1 receptor binding, rather than M4 receptor binding in the DLPFC.

5. Strengths and limitations

A key strength of the current study was that the subjects diagnosed with a psychotic disorder were medication free, and results did not have confounding effects of medication, or affected by indirect interaction effects between biperiden and antipsychotic medication affecting dopaminergic and serotonergic signalling. As cognitive symptoms often develop prior to the onset of psychotic disorder, alteration in M1 signaling has been proposed to be an upstream factor in the dysregulation of dopamine and serotonergic systems making it paramount to investigate medication free subjects (Vakalopoulos, 2014).

Another major strength was that differences in functional sensitivity to biperiden between controls and subjects with psychotic disorders was linked to regional M1 receptor binding in the subjects with psychotic disorders. These findings are critical to ongoing efforts to develop M1 antagonists to improve cognition (Erskine et al., 2019; Melanon et al., 2013). Also both biperiden and 125I-IDEX have been shown to preferentially bind to the M1 receptor (Bakker et al., 2015; Klinkenberg and Bliokland, 2011). Previous studies have used non-selective M1/A4 tracer IQNB or used scopolamine, an antagonist at the all muscarinic receptor subtypes, to investigate the role of the muscarinic system in schizophrenia or cognition which made it more difficult to attribute finding specifically to the M1 receptor. Notwithstanding this, we cannot rule out marginal effects on the functional response by biperiden blockade of the M4 receptor that has high density in the hippocampus. In addition, because both biperiden and 125I-IDEX are antagonists, they sample all M1 receptors rather than only those in a high-affinity state. The modulatory effects of the M1 receptor on the functional response will be mediated by those in a high affinity state, which we did not directly assess in this study.

Unfortunately, we were not allowed to acquire in-vivo M1 receptor data in the control subjects by the medical ethical board. Therefore, it was not possible to determine whether the lower hippocampal M1 binding that was shown to predict loss of functional activation in striatal-temporal regions during associative learning and memory was significantly reduced compared to controls. In addition, the subjects with a psychotic disorder included in this study displayed mild to moderate symptoms, as such findings may not translate well to more severely affected patients.

6. Conclusion

The current study showed an abnormally high hyperactivation of the parahippocampal gyrus during associative learning and memory in subjects diagnosed with a psychotic disorder in response to biperiden which may be related to loss of M1 mediated modulation over glutamate in these regions. Results further linked this hyperactivation to lower hippocampal M1 receptor binding, rather than M4 binding in the DLPFC. Lastly, subjects with psychotic disorder with greater negative symptom severity and lower hippocampal and DLPFC M1 binding showed greater loss of functional activation in the striatal-temporal circuitry. Performance on the PAL task together with negative symptom profile may be sensitive marker for greater therapeutic sensitivity to drugs targeting the muscarinic system.

Funding

This work was supported by the Dutch Organization for Health Research and Development (ZonMw 91112002) and by a personal grant to Thérèse van Amelsvoort (ZonMw-VIDI: 91712394). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Barbara J Sahakian is funded by the NIHR Cambridge Biomedical Research Centre (Mental Health and Neurodegeneration Themes) and the NIHR MedTech in vitro diagnostic Cooperative (MIC). This clinical trial was registered in the Dutch clinical trial registry under ID: NTR5094 (http://www.trialregister.nl).

Disclosure/conflicts of interest

The authors declare that, except for income received from their primary employer, no other financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service. Author BJS consults for Cambridge Cognition, Greenfield BioVentures and CassavaSciences. Author MWAC is a stakeholder of Nico-Lab Ltd. Authors declare no other personal financial holdings that could be perceived as constituting a potential conflict of interest.

References

Anagnostaras, S.G., Murphy, G.G., Hamilton, S.E., Mitchell, S.L., Rahnama, N.P., Nathanson, N.M., Silva, A.J., 2003. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 6, 51–58. https://doi.org/10.1038/nnet.992.

Andreasen, N.C., Hubbard, W., McNamara, C., Meller, J., Olson, N., Therme, J., Tookey, L., Tyrrell, G., 2000. Comprehensive Assessment of Symptoms and History. Bakker, G., Vingerhoets, C., Boucherie, D., Gaan, M, Bloemen, O., Eersels, J., Boijj, J., van Amelsvoort, T., 2018. Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis. Neurolmage Clin. 18, 713–719. https://doi.org/10.1016/j.nicl.2018.02.030.

Bakker, G., Vingerhoets, W.A.M., van Wieringen, J.-P., de Bruin, K., Eersels, J., de Jong, J., Chabid, Y., Rutten, B.P., Dufois, S., Watson, M., Mogg, A.J., Xiao, H., Crabtree, M., Collier, D.A., Faller, C.C., Barth, V.N., Broad, L.M., Bloemen, O.J., van Amelsvoort, T.A., Boijj, J., 2015. 123I-iodoepetide preferentially binds to the muscarinic receptor subtype M1 in vivo. J. Nucl. Med. 56, 317–322. https://doi.org/10.2967/jnumed.114.147488.

Barch, D.M., Cease, A., 2012. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn. Sci. 16, 27–34. https://doi.org/10.1016/j.tics.2011.11.015.

Barch, D.M., Sheffield, J.M., 2014. Cognitive impairments in psychotic disorders: common mechanisms and measurement. World Psychiatry 13, 224–232. https://doi.org/10.1002/wps.20145.

Barnett, J.H., Sahakian, B.J., Werners, U., Hill, K.E., Brazil, R., Gallagher, O., Bullmore, E.T., Jones, P.B., 2005. Visuospatial learning and executive function are independently impaired in first-episode psychosis. Psychol. Med. 35, 1031–1041. https://doi.org/10.1017/S0033291704004901.

Brem, A.-K., Ran, K., Pascual-Leone, A., 2013. Learning and memory. Handb. Clin. Neurol. 116, 693–737. https://doi.org/10.1016/B978-0-444-54349-2.00053-5.

Carruthers, S.P., Gurvich, C.T., Rossell, S.L., 2015. The muscarinic system, cognition and schizophrenia. Neurosci. Biobehav. Rev. https://doi.org/10.1016/j.neubiorev.2015.05.011.

De Rover, M., Pironti, V.A., McCabe, J.A., Acosta-Cabronero, J., Arana, F.S., Morein-Zamir, S., Hodges, J.R., Robbins, T.W., Fletcher, P.C., Nestor, P.J., Sahakian, B.J., 2011. Hippocampal dysfunction in patients with mild cognitive impairment: A functional neuroimaging study of a visuospatial paired associates learning task. Neuropsychology 49, 2060–2070. https://doi.org/10.1016/j.nicl.2011.03.037.

Dean, B., McLeod, M., Keriaux, D., McKenzie, J., Scarr, E., 2002. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 7, 1083–1091. https://doi.org/10.1038/sj.mp.4001199.

Erskine, D., Taylor, J.P., Bakker, G., Brown, A.J.H., Tasker, T., Nathan, P.J., 2019. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discov. Today. 00. https://doi.org/10.1016/j.drudis.2019.08.009.

Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., Montillo, A., Makris, N., Rosen, B., Dale, A.M., 2002. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuro 33, 341–355. https://doi.org/10.1016/S0885-3956(01)00569-X.

Gould, R.W., Grannan, M.D., Gunter, B.W., Ball, J., Bubser, M., Bridges, T.M., Weiss, J., Wood, M.W., Brandon, N.J., Duggan, M.E., Niswender, C.M., Lindsey, C.W., Conn, P.J., Jones, C.K., 2018. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VUB467154. Neuropharmacology 128, 492–502. https://doi.org/10.1016/j.neuropharm.2017.07.013.

Grasby, P.M., Frith, C.D., Paulsens, E., Friston, K.J., Frackowiak, R.S.J., Bolam, P.J., Dolan, R.J., 1995. The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task. Exp. Brain Res. 104, 337–348. https://doi.org/10.1007/BF00242019.

Green, M.F., Kern, R.S., Heaton, R.K., 2004. Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS, in: Schizophrenia

8
Research. Elsevier, pp. 41–51. https://doi.org/10.1016/j.schres.2004.09.009.
Grimaldi, R., Perucca, E., Ruberto, G., Gelmi, C., Trimarchi, F., Vollmann, M., Crema, A., 1986. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur. J. Clin. Pharmacol. 29, 725–737. https://doi.org/10.1007/BF00615970.
Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276.
Khan, A.H., Zaidi, S., 2017. Clozapine: improvement of negative symptoms of schizophrenia. Cureus 9, e1973. https://doi.org/10.7759/cureus.1973.
Kimura, Y., Ohue, M., Kitaura, T., Kikura, K., 1999. Amnesic effects of the anticholinergic drugs, trihexyphenidyl and biperiden: differences in binding properties to the brain muscarinic receptor. Brain Res. 834, 6–12. https://doi.org/10.1016/S0006-8993(99)01526-7.
Klinkenberg, I., Blokland, A., 2011. A comparison of scopolamine and biperiden as a novel rodent model for cholinergic cognitive impairment. Psychopharmacology 215, 549–566. https://doi.org/10.1007/s00213-011-2171-1.
Kraguljac, N.V., Srivastava, A., Lahti, A.C., 2013. Memory deficits in schizophrenia: a selective review of functional magnetic resonance imaging (fMRI) studies. Behav. Sci. (Basel, Switzerland) 3, 330–347. https://doi.org/10.3390/BS3030330.
Lavallée, J., Boisj, J., Linszen, D.H., Reneman, L., van Royen, E.A., 2001. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. [123I-IDEX SPECT study. Psychopharmacology 156, 53–57. https://doi.org/10.1007/s002130000679.
Levey, A.J., Kitt, C.A., Simonds, W.F., Price, D.L., Brann, M.R., 1991. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11, 3218–3226.
Lieberman, J.A., Girgis, R.R., Brucato, G., Moore, H., Provenzano, F., Kegeles, L., Javitt, D., Kunstiwitz, J., Wall, M.M., Corcoran, C.M., Schoebel, S.A., Small, S.A., 2018. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol. Psychiatry 23, 1764–1772. https://doi.org/10.1038/mp.2017.249.
Lodge, D.J., 2013. The MAM rodent model of schizophrenia. Curr. Protoc. Neurosci. Chapter 9 (Unit9), 43. https://doi.org/10.1002/9780471142301.nt094363.
Lodge, D.J., Grace, A.A., 2011. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol. Sci. 32, 507–513.
Mackenzie, N.E., Kowalchuk, C., Agarwal, S.M., Costa-Doohkan, K.A., Caragiaggio, F., Gerretsen, P., Chintoh, A., Remington, G.J., Taylor, V.H., Mueller, D.J., Graff-Guerrero, A., Hahn, M.K., 2018. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front. Psychiatry 9, 622. https://doi.org/10.3389/fpsyt.2018.00622.
McCutcheon, R.A., Ali-Dargham, A., Howes, O.D., 2019. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 42, 1-12.
Melencon, B.J., Tart, J.C., Panarese, J.D., Wood, M.R., Lindsley, C.W., 2013. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer’s disease. Drug Discov. Today 18, 1185-1199. https://doi.org/10.1016/j.drudis.2013.09.005.
Mitra, S., Mahintmani, T., Kavoor, A.R., Nizami, S.H., 2016. Negative symptoms in schizophrenia. Ind. Psychiatry J. 25, 135-144. https://doi.org/10.4103/ipj.ipj_30_15.
Mufson, E.J., Ginsberg, S.D., Ikonomovic, M.D., DeKosky, S.T., 2003. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J. Chem. Neuroanat. 26, 233–242. https://doi.org/10.1016/S0091-0618(03)00068-1.
Murray, G.K., Corlett, P.R., Fletcher, P.C., 2010. The neural underpinnings of associative learning in health and psychotic: How can performance be preserved when brain responses are abnormal? Schizophr. Bull. https://doi.org/10.1093/scan/nbs005.
Peräla, J., Suvisaari, J., Saarni, S., Kuoppasalmi, K., Iometsa, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hilttikka, J., Härkänen, T., Kikkinen, S., Lönnqvist, J., 2007. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64, 19–28. https://doi.org/10.1001/archpsychy.64.1.19.
Ragland, J.D., Blumenfeld, R.S., Ramsey, I.S., Yonelinas, A., Yoon, J., Solomon, M., Carter, C.S., Ranganath, C., 2012. Neural correlates of relational and item-specific encoding during working and long-term memory in schizophrenia. Neuroimage 59, 1719–1726. https://doi.org/10.1016/j.neuroimage.2011.08.055.
Ragland, J.D., Gur, R.C., Valdes, J., Turetsky, B.J., Elliott, M., Kohler, C., Sireg, S., Kanes, S., Gur, R.E., 2004. Event-related fMRI of frontaltemporal activity during word encoding and recognition in schizophrenia. Am. J. Psychiatry 161, 1004-1015. https://doi.org/10.1176/appi.ajp.161.6.1004.
Ragland, J.D., Laird, A.R., Ranganath, C., Blumenfeld, R.S., Gonzalez, S.M., Gladn, D.C., 2009. Prefrontal activation deficits during episodic memory in schizophrenia. Am. J. Psychiatry. https://doi.org/10.1176/appi.ajp.2009.08091307.
Scarr, E., Gibbons, A.S., Neo, J., Udawela, M., Dean, B., 2013. Cholinergic connectivity: it’s implications for psychiatric disorders. Front. Cell. Neurosci. 7, 55. https://doi.org/10.3389/fncel.2013.00055.
Sheffield, J.M., Karcher, N.R., Barch, D.M., 2018. Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol. Rev. 28, 509-533. https://doi.org/10.1007/s11065-018-9388-2.
Shekhar, A., Potter, W.Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., Bymaster, F.P., McKinzie, D.L., Felder, C.C., 2008. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165, 1033–1039. https://doi.org/10.1176/appi.ajp.2008.06091591.
Stam, M.K., Verwer, E.E., Booij, J., Adriaanse, S.M., de Bruin, C.M., de Wit, T.C., 2018. Performance evaluation of a novel brain-dedicated SPECT system. EJNMMI Phys. 5, 4. https://doi.org/10.1186/s40658-018-0203-1.
Sur, C., Mallora, P.J., Wittmann, M., Jacobson, M.A., Pascarella, D., Williams, J.B., Brandish, P.E., Pettibone, D.J., Scollnik, E.M., Conn, P.J., 2003. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. 100, 13674–13679. https://doi.org/10.1073/pnas.183561200.
Takeuchi, T., Duszkiewicz, A.J., Morris, R.G.M., 2014. The synaptic plasticity and memory hypothesis: encoding, storage and persistence. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369, 20130288. https://doi.org/10.1098/rstb.2013.0288.
Thor, C.A., Popolee, M., Stark, E., Edgerton, J.R., 2017. Effects of M1 and M4 activation on excitatory synaptic transmission in CA1. Hippocampus 27, 794. https://doi.org/10.1002/hipo.22752.
Vakalopoulos, C., 2014. The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis. Front. Pharmacol. 5, 277. https://doi.org/10.3389/fphar.2014.00277.